Jasper Therapeutics (JSPR)
Develops complement inhibitors and targeted antibodies for immunological disorders.
Something off on this page? Send us feedback.
Develops complement and antibody therapies for immunologically driven disorders through an acquired-or-licensed-asset model, outsourced clinical and manufacturing infrastructure, and licensing transactions; it has no approved commercial product.
Develops acquired and licensed antibodies and complement therapies for immunologically driven disorders. The current portfolio centers on KP-104, a bifunctional complement inhibitor in a clinical trial for rare renal disorders; briquilimab, an anti-KIT antibody being advanced toward regulatory discussion for SCID conditioning; and preclinical KP-701 for B-cell and autoantibody-mediated disease.
Operates by assembling externally originated or acquired drug assets and developing them through outsourced clinical and manufacturing infrastructure. A China subsidiary supports KP-104 trial execution, while KP-301 and KP-402 are licensed to Mirador for upfront and potential milestone economics.
Has no approved commercial product. Progress depends on clinical results and regulatory review, third-party execution, briquilimab licensing obligations, continued financing, and integration of the Kira acquisition.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 12, 2026 | Piper Sandler | Initiate | Rating: —Target: — | Target: $2 |
| May 15, 2026 | RBC Capital | Reiterate | Rating: —Target: $48 | Target: $3 |
| May 15, 2026 | TD Cowen | Downgrade | ||
| Jul 8, 2025 | BMO Capital | Downgrade | ||
| Jul 7, 2025 | Cantor Fitzgerald | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.3M · Total debt $270.0K · Total assets $11.8M · Shareholders' equity $1.4M
- Revenue
- $0
- Operating income
- −$9.2M
- Net income
- −$2.8M
No dividends on record.
| Institutions | 36.07% | 12.00M shares | |
|---|---|---|---|
| 47 holders · as of Jun 30, 2026 | |||
| Insiders | 3.02% | 1.01M shares | |
| 8 holders · as of Jul 22, 2026 | |||
| Strategic holders | 5.69% | 1.89M shares | |
| 2 holders · as of Feb 25, 2026 | |||
| Other | 55.22% | 18.37M shares | |
| remainder | |||
33.27M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (33.27M in the company's Sep 22, 2026 report, 16.25M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Velan Capital Master Fund LPInstitution | 9.13% | 3.04M | filed Aug 17, 2026 |
Velan Capital Investment Management LPInstitution | 8.02% | 2.67M | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 6.18% | 2.06M | filed Nov 14, 2025 |
Integrated Core Strategies (US) LLCStrategic | 4.88% | 1.62M | filed Feb 25, 2026 |
Acorn Capital Advisors, LLCInstitution | 4.32% | 1.44M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 20, 2026 | Matthew E. Ros | officer: Chief Operating Officer | +881 | |
| Jul 20, 2026 | Patrick J. Crutcher | director | +888 | |
| Sep 22, 2025 | Judith Anne Shizuru | director | +82,000 | $2.68 |
| Sep 22, 2025 | Ron Martell | director, officer: President and CEO | +82,000 | $2.68 |
| Sep 22, 2025 | Svetlana Lucas | director | +40,000 | $2.68 |
- AstraZeneca (ADR)
Marketed PNH complement franchise across C5 blockade and add-on therapy.
- Novartis (ADR)
Spans PNH, renal complement disease and chronic urticaria.
- Sanofi (ADR)
Marketed CSU biologic and Blueprint-derived KIT portfolio.
- Celldex Therapeutics
Closest anti-KIT antibody rival in late-stage chronic urticaria.
- Novo Nordisk (ADR)
Acquired MASP-3 program targets PNH and complement-mediated kidney disease.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Jasper Therapeutics | $0.6201 | +2.89% | $9.8M | — | — | — | — |
| AstraZeneca (ADR) | $167.17 | −0.55% | $260.70B | 25.2 | 15.7 | 4.2 | +6.4% |
| Novartis (ADR) | $140.40 | −0.41% | $267.96B | 21.3 | 14.9 | 4.8 | +0.9% |
| Sanofi (ADR) | $42.07 | −1.01% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| Celldex Therapeutics | $37.70 | −0.50% | $2.52B | — | — | 22,510.2 | −97.0% |
| Novo Nordisk (ADR) | $39.42 | −0.96% | $176.83B | 9.9 | 16.2 | 3.5 | +1.3% |
| Median | 23.3 | 15.7 | 4.2 | +1.3% |